Gene Therapy for CNS Disorders Market - Global Outlook and Forecast 2023-2028

Report ID: 1370514 | Published Date: Jan 2025 | No. of Page: 63 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Gene Therapy for CNS Disorders Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Gene Therapy for CNS Disorders Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Gene Therapy for CNS Disorders Overall Market Size
    2.1 Global Gene Therapy for CNS Disorders Market Size: 2021 VS 2028
    2.2 Global Gene Therapy for CNS Disorders Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Gene Therapy for CNS Disorders Players in Global Market
    3.2 Top Global Gene Therapy for CNS Disorders Companies Ranked by Revenue
    3.3 Global Gene Therapy for CNS Disorders Revenue by Companies
    3.4 Top 3 and Top 5 Gene Therapy for CNS Disorders Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Gene Therapy for CNS Disorders Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Gene Therapy for CNS Disorders Players in Global Market
        3.6.1 List of Global Tier 1 Gene Therapy for CNS Disorders Companies
        3.6.2 List of Global Tier 2 and Tier 3 Gene Therapy for CNS Disorders Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Gene Therapy for CNS Disorders Market Size Markets, 2021 & 2028
        4.1.2 Ex Vivo
        4.1.3 In Vivo
    4.2 By Type - Global Gene Therapy for CNS Disorders Revenue & Forecasts
        4.2.1 By Type - Global Gene Therapy for CNS Disorders Revenue, 2017-2022
        4.2.2 By Type - Global Gene Therapy for CNS Disorders Revenue, 2023-2028
        4.2.3 By Type - Global Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Gene Therapy for CNS Disorders Market Size, 2021 & 2028
        5.1.2 Hospitals
        5.1.3 Clinics
        5.1.4 Others
    5.2 By Application - Global Gene Therapy for CNS Disorders Revenue & Forecasts
        5.2.1 By Application - Global Gene Therapy for CNS Disorders Revenue, 2017-2022
        5.2.2 By Application - Global Gene Therapy for CNS Disorders Revenue, 2023-2028
        5.2.3 By Application - Global Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Gene Therapy for CNS Disorders Market Size, 2021 & 2028
    6.2 By Region - Global Gene Therapy for CNS Disorders Revenue & Forecasts
        6.2.1 By Region - Global Gene Therapy for CNS Disorders Revenue, 2017-2022
        6.2.2 By Region - Global Gene Therapy for CNS Disorders Revenue, 2023-2028
        6.2.3 By Region - Global Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Gene Therapy for CNS Disorders Revenue, 2017-2028
        6.3.2 US Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.3.3 Canada Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.3.4 Mexico Gene Therapy for CNS Disorders Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Gene Therapy for CNS Disorders Revenue, 2017-2028
        6.4.2 Germany Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.4.3 France Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.4.4 U.K. Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.4.5 Italy Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.4.6 Russia Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.4.7 Nordic Countries Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.4.8 Benelux Gene Therapy for CNS Disorders Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Gene Therapy for CNS Disorders Revenue, 2017-2028
        6.5.2 China Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.5.3 Japan Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.5.4 South Korea Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.5.5 Southeast Asia Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.5.6 India Gene Therapy for CNS Disorders Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Gene Therapy for CNS Disorders Revenue, 2017-2028
        6.6.2 Brazil Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.6.3 Argentina Gene Therapy for CNS Disorders Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Gene Therapy for CNS Disorders Revenue, 2017-2028
        6.7.2 Turkey Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.7.3 Israel Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.7.4 Saudi Arabia Gene Therapy for CNS Disorders Market Size, 2017-2028
        6.7.5 UAE Gene Therapy for CNS Disorders Market Size, 2017-2028
7 Players Profiles
    7.1 Gilead (Kite Pharma)
        7.1.1 Gilead (Kite Pharma) Corporate Summary
        7.1.2 Gilead (Kite Pharma) Business Overview
        7.1.3 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Major Product Offerings
        7.1.4 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Revenue in Global Market (2017-2022)
        7.1.5 Gilead (Kite Pharma) Key News
    7.2 Amgen (BioVex)
        7.2.1 Amgen (BioVex) Corporate Summary
        7.2.2 Amgen (BioVex) Business Overview
        7.2.3 Amgen (BioVex) Gene Therapy for CNS Disorders Major Product Offerings
        7.2.4 Amgen (BioVex) Gene Therapy for CNS Disorders Revenue in Global Market (2017-2022)
        7.2.5 Amgen (BioVex) Key News
    7.3 Novartis
        7.3.1 Novartis Corporate Summary
        7.3.2 Novartis Business Overview
        7.3.3 Novartis Gene Therapy for CNS Disorders Major Product Offerings
        7.3.4 Novartis Gene Therapy for CNS Disorders Revenue in Global Market (2017-2022)
        7.3.5 Novartis Key News
    7.4 Roche (Spark Therapeutics)
        7.4.1 Roche (Spark Therapeutics) Corporate Summary
        7.4.2 Roche (Spark Therapeutics) Business Overview
        7.4.3 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Major Product Offerings
        7.4.4 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Revenue in Global Market (2017-2022)
        7.4.5 Roche (Spark Therapeutics) Key News
    7.5 Bluebird Bio
        7.5.1 Bluebird Bio Corporate Summary
        7.5.2 Bluebird Bio Business Overview
        7.5.3 Bluebird Bio Gene Therapy for CNS Disorders Major Product Offerings
        7.5.4 Bluebird Bio Gene Therapy for CNS Disorders Revenue in Global Market (2017-2022)
        7.5.5 Bluebird Bio Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Gene Therapy for CNS Disorders Market Opportunities & Trends in Global Market
    Table 2. Gene Therapy for CNS Disorders Market Drivers in Global Market
    Table 3. Gene Therapy for CNS Disorders Market Restraints in Global Market
    Table 4. Key Players of Gene Therapy for CNS Disorders in Global Market
    Table 5. Top Gene Therapy for CNS Disorders Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Gene Therapy for CNS Disorders Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Gene Therapy for CNS Disorders Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Gene Therapy for CNS Disorders Product Type
    Table 9. List of Global Tier 1 Gene Therapy for CNS Disorders Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Gene Therapy for CNS Disorders Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Gene Therapy for CNS Disorders Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Gene Therapy for CNS Disorders Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Gene Therapy for CNS Disorders Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Gene Therapy for CNS Disorders Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Gene Therapy for CNS Disorders Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Gene Therapy for CNS Disorders Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2023-2028
    Table 30. Gilead (Kite Pharma) Corporate Summary
    Table 31. Gilead (Kite Pharma) Gene Therapy for CNS Disorders Product Offerings
    Table 32. Gilead (Kite Pharma) Gene Therapy for CNS Disorders Revenue (US$, Mn), (2017-2022)
    Table 33. Amgen (BioVex) Corporate Summary
    Table 34. Amgen (BioVex) Gene Therapy for CNS Disorders Product Offerings
    Table 35. Amgen (BioVex) Gene Therapy for CNS Disorders Revenue (US$, Mn), (2017-2022)
    Table 36. Novartis Corporate Summary
    Table 37. Novartis Gene Therapy for CNS Disorders Product Offerings
    Table 38. Novartis Gene Therapy for CNS Disorders Revenue (US$, Mn), (2017-2022)
    Table 39. Roche (Spark Therapeutics) Corporate Summary
    Table 40. Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Product Offerings
    Table 41. Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Revenue (US$, Mn), (2017-2022)
    Table 42. Bluebird Bio Corporate Summary
    Table 43. Bluebird Bio Gene Therapy for CNS Disorders Product Offerings
    Table 44. Bluebird Bio Gene Therapy for CNS Disorders Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Gene Therapy for CNS Disorders Segment by Type in 2021
    Figure 2. Gene Therapy for CNS Disorders Segment by Application in 2021
    Figure 3. Global Gene Therapy for CNS Disorders Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Gene Therapy for CNS Disorders Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Gene Therapy for CNS Disorders Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Gene Therapy for CNS Disorders Revenue in 2021
    Figure 8. By Type - Global Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    Figure 12. US Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    Figure 16. Germany Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 17. France Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    Figure 24. China Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 28. India Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    Figure 30. Brazil Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Gene Therapy for CNS Disorders Revenue Market Share, 2017-2028
    Figure 33. Turkey Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Gene Therapy for CNS Disorders Revenue, (US$, Mn), 2017-2028
    Figure 37. Gilead (Kite Pharma) Gene Therapy for CNS Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Amgen (BioVex) Gene Therapy for CNS Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Novartis Gene Therapy for CNS Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Bluebird Bio Gene Therapy for CNS Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
63
Frequently Asked Questions
Gene Therapy for CNS Disorders Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Gene Therapy for CNS Disorders Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Gene Therapy for CNS Disorders Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports